USPTO Art Unit 1617 Prosecution Statistics

Art Unit Information

Art Unit: 1617
Group: 1610
Tech Center: 1600
Total Cases: 15,264
Last Active: June 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19247635Coralline Hydroxyapatite And Preparation Method ThereofJune 2025December 2025Allow601YesNo
19230961METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONJune 2025December 2025Allow611NoNo
19224452METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONMay 2025November 2025Allow620YesNo
19216474METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONMay 2025October 2025Allow511NoNo
19205510ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRMay 2025June 2025Allow100YesNo
19177269ORAL FORMULATION OF A THERAPEUTIC COMPOUNDApril 2025October 2025Abandon710YesNo
19174612OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITORApril 2025August 2025Allow511NoNo
19172077Methods of administering safe colon cleansing compositionsApril 2025December 2025Allow810NoNo
19172483CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITISApril 2025July 2025Allow300NoNo
19075217MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2025August 2025Allow510NoNo
19062757Methods of administering safe colon cleansing compositionsFebruary 2025August 2025Allow610NoNo
19042975BIOBASED WOUND HEALING PREPARATION AND METHOD OF PREPARATION THEREOFJanuary 2025June 2025Allow410YesNo
19034843Microsphere-Based Injectable Celecoxib FormulationJanuary 2025September 2025Allow820YesNo
19025668METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONJanuary 2025April 2025Allow310YesNo
19021882STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINEJanuary 2025July 2025Allow611YesNo
19011043ALBUTEROL AEROSOL SUSPENSION FORMULATION FOR ORAL INHALATION WITH HIGH AMOUNT OF GREEN PROPELLANT HYDROFLUOROOLEFIN (HFO) AND FREE OF CO-SOLVENTJanuary 2025May 2025Allow411YesNo
18991280PREPARATION METHOD FOR THREE-DIMENSIONAL GELATIN SCAFFOLD WITH INTERCONNECTED PORES AND APPLICATION THEREOFDecember 2024January 2026Allow1320NoNo
18976941Method and Composition for an Improved Bioavailability Delivery SystemDecember 2024August 2025Allow811YesNo
18977672WOUND HEALING DRESSINGS AND FORMULATIONS AND METHODS OF USE THEREOFDecember 2024February 2026Allow1521YesNo
18967829Formulations of EnzalutamideDecember 2024May 2025Allow610YesNo
18962073BURN WOUND TREATMENTNovember 2024April 2025Allow511NoNo
18954292IMPLANTS FOR CARTILAGE AND RELATED DEVICES AND METHODSNovember 2024October 2025Allow1120YesNo
18950997CANCER TREATMENT METHOD WITH NANOCOMPOSITENovember 2024January 2025Allow210NoNo
18939325COMPOSITIONS, METHODS, AND SYSTEMS IN TREATING PRESBYOPIANovember 2024May 2025Allow611YesNo
18913776DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIESOctober 2024February 2025Allow510NoNo
18912152USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGSOctober 2024November 2025Allow1331YesYes
18911121METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTIONOctober 2024May 2025Allow711YesNo
18910243SKINCARE COOLING PRODUCT, METHOD OF MAKING, AND METHOD OF USING THE SAMEOctober 2024April 2025Allow611YesNo
18909566DERMAL PATCH AND SYSTEMS, KITS, AND METHODS ASSOCIATED THEREWITHOctober 2024August 2025Allow1020NoNo
18900544METHODS OF INSECT CONTROL FOR AN ANIMAL, PRODUCTS THEREOF AND METHODS FOR THEIR PREPARATIONSeptember 2024July 2025Allow1010NoNo
18898561ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGELSeptember 2024December 2024Allow200NoNo
18893280COMPOSITIONS AND METHODS FOR DELIVERY OF RNASeptember 2024June 2025Allow910NoNo
18891739ION CHANNEL PROSTHETIC COMPOSITIONS COMPRISING LIPID-COATED CRYSTALS OF AMPHOTERICIN BSeptember 2024May 2025Allow821NoNo
18842531SOFTGEL CAPSULES AND A METHOD FOR PREPARING THE SOFTGEL CAPSULESAugust 2024July 2025Allow1120NoNo
18809240COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONSAugust 2024March 2026Allow1931YesNo
18795731COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795711COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795683COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795653Surfactin-Based Lipopeptide for mRNA DeliveryAugust 2024February 2025Allow610YesNo
18795667Surfactin-Based Lipopeptide for mRNA DeliveryAugust 2024February 2025Allow610NoNo
18792849Methods of administering safe colon cleansing compositionsAugust 2024February 2025Allow710NoNo
18793091Herbicidal compositions comprising trifludimoxazinAugust 2024September 2024Allow200YesNo
18778340SYNTHESIS AND CHARACTERIZATION OF GLAUCONITE-BASED SILICATE NANORODS AS ANTICANCER AGENTJuly 2024October 2024Allow310YesNo
18765361MAGNETIC NANO-DRUG WITH DOUBLE TARGETING VEGF-VEGFR, AND PREPARATION METHOD AND APPLICATION THEREOFJuly 2024December 2024Allow511NoNo
18763977USE OF TRIMANGANESE TETRAOXIDE PARTICLES IN PREPARATION OF VACCINE ADJUVANTJuly 2024August 2025Allow1311YesNo
18758007COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAJune 2024December 2024Allow610NoNo
18725024COMPOSITION AND METHOD OF INDUCING SYSTEMIC ACQUIRED RESISTANCE (SAR) IN PLANTSJune 2024March 2026Allow2010YesNo
18752293LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOFJune 2024January 2026Allow1930NoNo
18720721EFFECT PIGMENTS HAVING A REFLECTIVE CORE AND SEMICONDUCTOR LAYERSJune 2024March 2025Allow910NoNo
18743526Methods of administering safe colon cleansing compositionsJune 2024December 2024Allow720YesNo
18742182GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIRJune 2024December 2025Allow1820NoNo
18739871HORTICULTURAL HYDROGELSJune 2024December 2024Allow620NoNo
18736965OLANZAPINE COMPOSITIONS AND METHODS OF USEJune 2024December 2024Allow611NoNo
18737814COATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAMEJune 2024January 2026Allow2020YesNo
18732895Method of Treating Oxidative Stress in Skin and Compositions ThereforJune 2024January 2026Allow1921YesNo
18731812AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATIONJune 2024March 2026Abandon2111NoNo
18673405CELLULOSE NANOCRYSTAL-BASED EMULSIONS AND USES THEREOFMay 2024October 2025Allow1711NoNo
18672297PRODUCT, SYSTEM AND METHOD FOR AN IMPROVED FERTILIZERMay 2024December 2025Abandon1910NoNo
18668674CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDEMay 2024November 2025Abandon1811NoNo
18711575INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USEMay 2024May 2025Allow1211YesNo
18664867METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONMay 2024March 2025Allow1011YesNo
18665291COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISMMay 2024October 2025Abandon1710NoNo
18662099Surfactin-Based Lipopeptide for mRNA DeliveryMay 2024November 2024Allow611NoNo
18660885BLETILLA STRIATA POLYSACCHARIDE IRON COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2024March 2025Abandon1011NoNo
18659629AQUEOUS LIQUID PREPARATIONMay 2024January 2025Allow811YesNo
18708128METHOD FOR PRODUCING SARCOPENIA-INHIBITING FOOD PRODUCT, SARCOPENIA-INHIBITING FOOD PRODUCT, AND MUSCLE-ENHANCING FOOD PRODUCTMay 2024October 2025Allow1761YesNo
18654817KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALINGMay 2024July 2025Abandon1410NoNo
18654308VETERINARY PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTIONMay 2024August 2025Allow1610NoNo
18653604COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLSMay 2024January 2026Allow2111NoNo
18650542FORMULATIONS OF AG10April 2024September 2025Allow1610YesNo
18703622PERFUMING COMPLEX, PERFUMING COMPOSITION AND PERFUMED AQUEOUS COMPOSITION OF NATURAL ORIGINApril 2024March 2025Allow1010NoNo
18637675Fibrous Structures Comprising Particles and Methods for Making SameApril 2024July 2025Allow1500NoNo
18633608SYSTEMS AND METHODS FOR APPLICATION OF ACTIVE INGREDIENTS TO CANNABISApril 2024July 2025Abandon1510NoNo
18630275SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTApril 2024December 2025Allow2020NoNo
18629707METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERYApril 2024June 2025Allow1412YesNo
18626374USE OF DESTRUCTURIZED STARCH AS A THICKENING AGENT AND COMPOSITIONS CONTAINING ITApril 2024June 2025Abandon1510NoNo
18627293METHODS AND COMPOSITIONS FOR TREATING SEPSISApril 2024November 2025Abandon1911NoNo
18623943ZINC-[GAMMA]-PGA COMPOSITIONS AND METHODS FOR TREATING CANCERApril 2024January 2026Abandon2120NoNo
18623761COMPACTABLE ORAL FORMULATIONS OF IBUTAMORENApril 2024June 2025Allow1421YesNo
18621501ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTMarch 2024August 2025Allow1711NoNo
18609954MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTSMarch 2024February 2025Allow1110YesNo
18607924CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATIONMarch 2024December 2025Allow2110NoNo
18606407STABLE CHLORINATED ALKALINE PRODUCTSMarch 2024March 2026Allow2410YesNo
18606372COMPOSITIONS, METHODS, AND SYSTEMS IN TREATING PRESBYOPIAMarch 2024May 2025Abandon1421NoNo
186070935-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONSMarch 2024September 2024Allow601NoNo
18606877Pharmaceutical Complex for Radioprotection, Preparation Method, and Applications thereofMarch 2024May 2025Abandon1421NoNo
18692195POROUS AEROGEL SCAFFOLD, METHOD OF PREPARING THE SAME AND USE THEREOFMarch 2024August 2025Allow1700YesNo
18602984DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFMarch 2024November 2025Allow2040YesNo
18602972DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFMarch 2024January 2026Allow2240NoNo
18602676ADIPOSE TISSUE MATRICESMarch 2024April 2025Abandon1310NoNo
18593225MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2024February 2025Allow1110YesNo
18582837POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHERFebruary 2024April 2025Allow1411YesNo
18581460Treatment of Vomiting and Nausea with Minimum Dose of OlanzapineFebruary 2024April 2025Allow1310NoNo
18444485Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereofFebruary 2024April 2025Allow1421NoNo
18443689NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024May 2024Allow300YesNo
18433701METHOD FOR CONTROLLING THE GROWTH OF UNDESIRABLE VEGETATIONFebruary 2024March 2025Abandon1301NoNo
18430003NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024January 2025Abandon1110NoNo
18430571NON-PULVERULENT ANTISUN COMPOSITION COMPRISING A POLAR OIL PHASE AND HYDROPHOBIC SILICA AEROGEL PARTICLESFebruary 2024January 2026Allow2330NoNo
18445785Microdaily EMF Protects Against Oxidative and Inflammatory Damage, and Acute and Late Adverse Effects of EMF RadiationFebruary 2024August 2025Allow1930YesNo
18429056DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOFJanuary 2024July 2024Allow511YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1617.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
539
Examiner Affirmed
379
(70.3%)
Examiner Reversed
160
(29.7%)
Reversal Percentile
36.0%
Lower than average

What This Means

With a 29.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
2250
Allowed After Appeal Filing
506
(22.5%)
Not Allowed After Appeal Filing
1744
(77.5%)
Filing Benefit Percentile
10.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1617 - Prosecution Statistics Summary

Executive Summary

Art Unit 1617 is part of Group 1610 in Technology Center 1600. This art unit has examined 15,264 patent applications in our dataset, with an overall allowance rate of 44.9%. Applications typically reach final disposition in approximately 35 months.

Comparative Analysis

Art Unit 1617's allowance rate of 44.9% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1617 receive an average of 2.30 office actions before reaching final disposition (in the 78% percentile). The median prosecution time is 35 months (in the 28% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.